Related Experiment Video

Updated: Jul 8, 2026

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

In vitro activity of AR-709 against Streptococcus pneumoniae

W T M Jansen1, A Verel, J Verhoef

  • 1University Medical Center Utrecht, Medical Microbiology Dept., G 04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. w.t.m.jansen@umcutrecht.nl

Antimicrobial Agents and Chemotherapy
|January 9, 2008
PubMed

Insights

The novel antibiotic AR-709 demonstrates potent in vitro activity against Streptococcus pneumoniae. This includes effectiveness against both drug-susceptible and multidrug-resistant strains, offering potential for respiratory tract infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Community-acquired respiratory tract infections (RTI) pose a significant public health challenge.
  • Streptococcus pneumoniae is a primary causative agent of both upper and lower RTIs.
  • Emergence of multidrug-resistant (MDR) pneumococcal strains necessitates the development of novel antibiotics.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of AR-709, a novel diaminopyrimidine antibiotic.
  • To assess AR-709 efficacy against a diverse panel of Streptococcus pneumoniae isolates.

Main Methods:

  • In vitro susceptibility testing was performed.
  • The study utilized 151 Streptococcus pneumoniae strains collected from various European countries.
  • AR-709 activity was assessed against both drug-susceptible and multidrug-resistant pneumococci.

Main Results:

  • AR-709 exhibited excellent in vitro activity against all tested Streptococcus pneumoniae strains.
  • The antibiotic demonstrated potent efficacy against both susceptible and multidrug-resistant pneumococcal isolates.

Conclusions:

  • AR-709 shows promising in vitro activity for the potential treatment of Streptococcus pneumoniae infections.
  • Its effectiveness against MDR strains suggests a valuable role in combating resistant bacterial pathogens.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...